AI assistant
FENNEC PHARMACEUTICALS INC. — Director's Dealing 2024
May 21, 2024
35599_dirs_2024-05-21_158b1de5-b842-44f7-ac0d-381c8589baf1.zip
Director's Dealing
Open in viewerOpens in your device viewer
SEC Form 4 — Statement of Changes in Beneficial Ownership
Issuer: FENNEC PHARMACEUTICALS INC. (FENC)
CIK: 0001211583
Period of Report: 2024-05-16
Reporting Person: Andrade Robert (N/A)
Derivative Transactions
| Date | Security | Exercise Price | Code | Shares | A/D | Expiration | Underlying | Ownership |
|---|---|---|---|---|---|---|---|---|
| 2024-05-16 | Stock Option (right to buy) | $7.12 | A | 100000 | Acquired | 2034-05-16 | Common Shares (100000) | Direct |
| 2024-05-16 | Restricted Share Unit (right to receive value of a share) | $0 | A | 50000 | Acquired | 2034-05-16 | Common Shares (50000) | Direct |
Footnotes
F1: On May 16, 2024, Robert Andrade was granted incentive stock options to purchase 100,000 shares of the issuers common shares pursuant to the Issuer's 2020 Equity Incentive Plan.
F2: One-third of the shares subject to this option may be exercised as of May 16, 2025 ("Vesting Commencement Date"). One twenty-fourth of the shares subject to this option shall vest and may be exercised as of the last day of each month following the Vesting Commencement Date. As of April 30, 2027, 100% of the total number of shares subject to this option shall be vested.
F3: On May 16, 2024, Robert Andrade was awarded restricted share units to acquire 50,000 shares of the issuers common shares pursuant to the Issuer's 2020 Equity Incentive Plan.
F4: One-third of the shares subject to this award may be released from restriction as of May 16, 2025 ("Vesting Commencement Date"). One twenty-fourth of the shares subject to this award shall be released from restriction as of the last day of each month following the Vesting Commencement Date. As of April 30, 2027, 100% of the total number of shares subject to this award shall be releaseed.